Blog
Latest updates, new compound writeups, and other additions.
BPC-157 vs. TB-500: What's the Difference?
Two of the most commonly paired peptides in recovery-focused research: how they differ, why they're stacked together so often, and what each one is specifically studied for.
July 27, 2026The FDA Peptide Vote: What Actually Happened This Week
An FDA advisory committee just voted on seven peptides, including BPC-157 and TB-500. Here's what the vote actually means, and what it doesn't.
July 27, 2026GLP-1 Peptides Explained: Semaglutide, Tirzepatide, Retatrutide, and Cagrilintide Compared
Four metabolic peptides get lumped together as "GLP-1 drugs," but they don't all work the same way. Here's how each one's mechanism differs, and where each stands in terms of track record.
July 27, 2026Is Retatrutide a "GLP-3" Drug? Not Exactly
Retatrutide gets nicknamed the "GLP-3" compound online because it hits a third receptor beyond semaglutide and tirzepatide. Here's why that name doesn't quite hold up.
July 27, 2026GLP-2 Isn't a Weight-Loss Peptide: Here's What It Actually Is
It's easy to assume GLP-2 is just the next step after GLP-1 drugs like semaglutide. It isn't: it's a different hormone with a completely different job.